Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on September 24, 2019, to announce the presentation of clinical results for its investigational anti-PD-1 antibody, tislelizumab. These important data updates were shared at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in China. The company highlighted results from three ongoing clinical trials, with five oral presentations dedicated to tislelizumab, underscoring the focus and progress of this key pipeline asset.
Key Highlights
- 1Presentation of new/updated clinical results for tislelizumab from three ongoing trials at CSCO.
- 2Tislelizumab data featured in five oral presentations, indicating significant progress and investor interest.
- 3Broader data presentation at CSCO included four poster sessions covering tislelizumab, zanubrutinib, and pamiparib.
- 4The event took place from September 18-22, 2019, in Xiamen, China.
- 5This filing serves as notification of the press release detailing these clinical updates.
- 6The press release is filed as Exhibit 99.1 to the Form 8-K.